🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Dr Faizi A. Jamal shares how EchoGo® Heart Failure supports effective clinical decisions enhancing confidence in HFpEF diangoses. hubs.la/Q03bTzMW0

ASE’s “ATTR-CM: Advancement & Opportunities Forum” is encouraging interactive discussions between key thought leaders, researchers & industry experts on the future of ATTR-CM care. ✔️Best practices & advancements ✔️Expanding opportunities ✔️Addressing needs & collab. solutions

🚀 Transthyretin Amyloid Cardiomyopathy: A Paradigm for Advancing Precision Medicine 🚀 doi.org/10.1093/eurhea… Transthyretin amyloid cardiomyopathy (ATTR-CM) is emerging as a model for precision medicine, transforming what was once considered a rare and fatal disease into one

Early detection of Cardiac Amyloidosis is crucial as new targeted therapies emerge. Our FDA-cleared breakthrough AI solution, EchoGo® Amyloidosis, provides insights to help detect patients and guide timely treatment. Our Founder and CEO Ross Upton PhD shares key takeaways on a

📣 Introducing an exciting new update to EchoGo® Heart Failure – now featuring probability scoring to assess a patient's likelihood of #HFpEF from a single #EchoFirst clip! Empowering more informed decisions & reducing diagnostic uncertainty. hubs.la/Q03dR96s0 #ACC25

External validation of a deep-learning AI by Ultromics to detect HFpEF using single #EchoFirst clip shows AI reduces uncertainty of diagnosis when combined w/ clinical scores. Jordan Strom, MD, MSc, FACC, FASE et al in Nature Communications: rdcu.be/ee1lL

Ultromics is at #ACC25! Join us at booth 22034 to see how we’re transforming heart failure detection! We’re unveiling our latest update—AI-powered probability scoring —plus showing our newly FDA cleared breakthrough for cardiac amyloidosis detection. Don't miss these sessions👇

Patient symptoms aren’t matching the diastology? EchoGo® Heart Failure can help in the diagnostic process. Dr. Andres Schuster from UH Harrington Heart & Vascular Institute shares his experience using EchoGo® Heart Failure, powered by AI, to help detect #HFpEF. Read more in Cath Lab Digest:

🤔

Claude says: claude.ai/share/e8552eec… ChatGPT says: chatgpt.com/share/6853a136…

In a new interview, Dr. Andres Schuster at UH Harrington Heart & Vascular Institute discusses recent cases where EchoGo® Amyloidosis supported the positive identification of patients with cardiac amyloidosis. Learn more how EchoGo® Amyloidosis, powered by #AI, identifies cardiac #amyloidosis, supporting

Wonderful to have more tools to suspect and diagnose amyloidosis! With therapies now available to benefit patients, the key is early diagnosis.

🚨 ASE Guideline Update! The new ASE Diastolic Function Guidelines are out — and our paper (AI for detecting HFpEF) is cited! 🎯 📄 Link to full guidelines - our paper is cited in “Application of AI to the Assessment of LV Diastolic Function” section: onlinejase.com/article/S0894-…

📢 New #EHJ study! Our AI screening tool for echo — EchoGo® Amyloidosis — detects cardiac amyloidosis, a life-threatening condition, with high accuracy. Developed with Mayo Clinic The University of Chicago, tested with 18 global sites. See paper & release: ultromics.com/press-releases… #CardioTwitter

🚨New Publication Alert: Our Landmark Study Published in the European Heart Journal! We’re proud to share that our latest study demonstrates that EchoGo® Amyloidosis, Ultromics’ FDA-cleared AI tool, significantly improves the detection of cardiac amyloidosis using a single

So grateful to be part of this amazing team of investigators. This project took a village, spanning 19 medical centers & 4 continents. Particular thanks to Roberto M Lang (in memorium) Dr.Patricia Pellikka, & the amazing Ultromics team for their tireless work, support, and mentorship

Just published in European Heart Journal — a global milestone in AI-powered cardiac care. UChicago Medicine’s Drs. Jeremy Slivnick and Roberto Lang (in memoriam) helped lead a multi-center, international study — in collaboration with Dr. Patricia Pellikka (Mayo Clinic) and the

Thanks for your precious help with the paper and your leadership of the international collaboration, Jeremy Slivnick ! This was a dream team!

Could AI diagnose your heart disease? In a new study, an AI model outperformed current clinical scoring systems for accurately detecting and identifying cardiac amyloidosis, potentially helping doctors give patients earlier, more effective treatments. uchicagomedicine.org/forefront/rese…

Mayo Clinic and Ultromics' AI-powered echocardiography detects cardiac amyloidosis, a life-threatening heart condition, with high sensitivity and accuracy. Early detection is key. Learn more: mayocl.in/44Etbii